World CDx Frankfurt
Le Meridien Parkhotel Frankfurt
Wiesenhuettenplatz 28-38
Frankfurt , Germany
World CDx Frankfurt
World CDx Frankfurt
Le Meridien Parkhotel Frankfurt
Wiesenhuettenplatz 28-38

Schedule of Presentations:

Tuesday, March 19, 2013
08:00:00 Registration & networking
09:00:00 Regulation & Clinical Development of CDx
09:00:00 Chairman’s opening remarks Scott Woodward
09:10:00 Where are we now? Recent investment paradigms & rapidly changing criteria for investments in the face of the personalised movement Scott Woodward
09:40:00 Effective alliance management & collaborating to build innovative investment in CDx/MDx Kevin DeGeeter
10:10:00 Morning refreshments & speed networking
11:40:00 Panel Session: Applying forward thinking analysis to harness untapped potential of personalised medicine Chandra P. Leo
12:25:00 Finding the ideal in investment deal structuring in the personalised medicine space
13:00:00 B: Development and Application of Biomarkers in Early Phase Clinical Trials Richard Kennedy, Charlie Gourley
13:05:00 Networking Lunch
14:05:00 Panel Session: VC investment the savior of biotech? Exploring VC methods for evaluating what small companies & start-ups need to achieve for liquidity and/or partnership success Kees Groen, Anne Burger
14:50:00 Case study: A novel single biomarker for predicting bone relapse in early stage breast cancer patients - clinical implications Joël Jean-Mairet
15:20:00 Afternoon refreshments
15:50:00 Exploring health economic strategies: Is improving reimbursement paradigms the first step to encouraging more investment into personalised medicine? Ryan Richardson
16:20:00 Capturing the value of CDx in the face of reimbursement uncertainty: Cutting edge strategies for ROI success
16:30:00 C: Global Commercial Strategies for Targeted Therapeutics Kristin Pothier, Gary Gustavsen
16:50:00 Where are we headed? Healthcare investment in an individualised future Andrew Baum
17:20:00 Chairman’s closing remarks
17:35:00 Networking drinks
Wednesday, March 20, 2013
04:40:00 Blueprint for integration of genomic techniques into CDx development Hans Lehrach
08:00:00 Registration & networking
09:00:00 Chairman’s opening remarks
09:10:00 Where we are, where we are headed in the global Dx landscape
09:40:00 Applications of genomic & genetic information in personalised medicine development & innovation Sir John Burn
10:10:00 Morning refreshments & speed networking
11:40:00 Partnering in Biomarker Driven Clinical Trials Michael Sloan
11:40:00 Ensuring optimal use of biomarkers in clinical POC for development of companion diagnostics
12:10:00 Cancer mutations and resistance to targeted therapies
12:10:00 Challenges & solutions to moving sequencing into national health services Anna Pokorska Bocci
12:40:00 Challenges and Opportunities for Drug Development with Biomarker Negative Populations Richard Buller
12:40:00 Pharma/Dx collaboration: Mitigating risk, maximizing returns for both parties Peter Collins
13:10:00 Networking Lunch
14:10:00 Overcoming stratification challenges in onco-haematology
14:10:00 Business implications of stratifying a drug across diagnostic and pharma companies, learnings from Roche’s in-house model
14:40:00 Enhancing drug safety in translational medicine Steve White
14:40:00 Examining the CDx M&A model today Guy Greiveldinger
15:10:00 Companion diagnostics and the drug-diagnostic co-development: Current status and future trends Jan Trøst Jørgensen
15:10:00 Clinical Trial Design in the Age of Personalised Medicine
15:40:00 Afternoon refreshments
16:10:00 Successfully converting pharmacogenomic research into translational medicine & patient care
17:10:00 Computational strategies for biomarker discovery and CDx development Amir Handzel
17:40:00 Chairman’s Closing Remarks
18:00:00 Networking drinks
Thursday, March 21, 2013
08:00:00 Registration & networking
09:00:00 Chairman’s opening remarks
09:10:00 Changing the way we view CDx through development of “Targeted Diagnostics” Daniel O’Shannessy
09:40:00 Understanding the measure of CTSs in the context of personalised medicine
10:10:00 Accelerate the development of tissue-based CDx by seamlessly integrating image analysis with data mining throughout the drug development process
10:40:00 Clinical applications of CTCs: Embracing the companion diagnostic potential
10:40:00 Morning refreshments & networking
11:10:00 Perfecting robust pharmacodynamic (PD) biomarker measurement during early stage clinical development David Henderson
11:10:00 The EU framework on medical devices and companion diagnostics in comparison to US legislation Alexander Natz
11:40:00 Mapping a future CDx regulatory vision for Europe: Short, medium & long term
11:40:00 Triple Companion Dx for Predicting Response to Bevacizumab, Cetuximab and FOLFOX in Metastatic Colorectal Cancer using Next Gen Sequencing
12:10:00 Early development biomarker programs in pRED: maximising early stage compound efficacy
12:10:00 Successful CDx assessment in an era of costconsciousness Nick Crabb
12:40:00 Networking Lunch
12:40:00 Networking Lunch
13:40:00 Bridging research & clinical care: Translating biomarker & diagnostic tools into patient treatment Alain van Gool
13:40:00 Successfully integrating personalised medicine into public health interventions
14:10:00 Exploring the most effective regulatory options & routes for CDx success
14:10:00 Towards biomarker-based personalised healthcare in common metabolic diseases Mark Brönstrup
14:40:00 Beyond cancer: Mapping the progress of personalised medicine in infectious disease
14:40:00 Charting the effects of recent legislation & regulation on the European CDx landscape Birka Lehmann
15:10:00 Afternoon refreshments
15:40:00 FUTURE OUTLOOK PANEL: What will have the biggest impact on CDx development & innovation over the coming years? Mark Brönstrup, Nick Crabb , Daniel O’Shannessy, Alain van Gool
16:25:00 Chairman’s Closing Remarks
16:45:00 Close of Conference
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.